ArticleBreast cancer research : BCR2025
Autoimmune thyroiditis promotes breast cancer progression: exploratory role of thyroid hormone receptor beta signaling disruption.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global evolution of ferroptosis research: a comprehensive bibliometric analysis of publication trends, geographic patterns, pharmacological innovation, and translational progress from inception through 2025.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between autoimmune thyroiditis (AITD) and breast cancer has been frequently reported in epidemiological studies. However, the underlying mechanisms remain unclear, particularly regarding whether AITD-related antibodies contribute to breast cancer progression. We hypothesized that thyroid hormone receptor beta (THRβ) autoantibodies may mediate this association by disrupting THRβ signaling in breast cancer cells.
methodsAn AITD-breast cancer comorbidity model was established by simultaneously inducing EAT and orthotopically transplanting breast cancer cells in NOD/ShiLtJ mice. Histological evaluation (H&E staining), ELISA, and immunohistochemistry were used to assess thyroiditis induction and tumor characteristics. In vitro, 5-ethynyl-2'-deoxyuridine (EdU), Cell Counting Kit-8 (CCK-8), scratch, and Transwell assays were performed to evaluate the effects of THRβ-reactive antibody on the proliferation and migration of breast cancer cells. The antagonistic effect of the selective THRβ agonist Resmetirom was also examined. Additionally, The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were analyzed to investigate THRβ expression and its prognostic relevance in breast cancer tissues.
resultsIn vivo experiments demonstrated that the AITD mouse model exhibited significantly elevated serum levels, accompanied by increased tumor formation rate and proliferative activity of breast cancer cells. In vitro, directly promoted proliferation and migration of MDA-MB-231 and MCF-7 cells, while the selective THRβ agonist Resmetirom effectively counteracted these effects. Bioinformatics analysis revealed that THRβ expression was downregulated in breast cancer tissues, and higher expression was associated with improved disease-free survival.
conclusionThis study suggests that THRβ-reactive antibody may promote breast cancer progression by disrupting THRβ signaling, indicating a mechanistic link between AITD and breast cancer comorbidity. Targeting THRβ signaling with agents such as Resmetirom may hold therapeutic potential in this immune-related oncologic context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.